Krimo Bouabdallah Selected Research

Doxorubicin (Adriamycin)

10/2023	Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
1/2022	Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.
1/2021	A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
1/2019	PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Krimo Bouabdallah Research Topics

Disease

22	Lymphoma (Lymphomas) 03/2024 - 05/2008
16	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 04/2024 - 07/2012
15	Hodgkin Disease (Hodgkin's Disease) 10/2023 - 03/2008
11	B-Cell Lymphoma (Lymphoma, B Cell) 01/2024 - 04/2011
9	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 02/2023 - 01/2007
9	Neoplasms (Cancer) 01/2023 - 01/2007
5	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 11/2023 - 01/2007
4	Residual Neoplasm 03/2024 - 11/2020
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 02/2022 - 01/2020
3	Pneumonia (Pneumonitis) 01/2021 - 03/2013
3	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2017 - 01/2012
3	Disease Progression 01/2017 - 07/2012
2	Infections 12/2023 - 01/2017
2	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 02/2023 - 01/2013
2	Cytokine Release Syndrome 11/2021 - 01/2021
2	Neutropenia 10/2018 - 01/2017
2	Pathologic Complete Response 01/2018 - 01/2017
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2017 - 12/2012
2	Graft vs Host Disease (Graft-Versus-Host Disease) 05/2015 - 01/2011
1	Cytopenia 01/2024
1	Macrophage Activation Syndrome 10/2022
1	Pain (Aches) 02/2022
1	Fatigue 02/2022
1	Hypertension (High Blood Pressure) 01/2021
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2021
1	Metabolic Diseases (Metabolic Disease) 01/2020
1	Infertility (Sterility) 01/2019
1	Gastroenteritis 06/2018
1	Mucositis 06/2018
1	Colitis 06/2018

Drug/Important Bio-Agent (IBA)

15	Rituximab (Mabthera)FDA Link 04/2024 - 01/2007
8	obinutuzumabIBA 01/2024 - 08/2013
7	Bendamustine Hydrochloride FDA Link 03/2024 - 01/2013
6	Cytarabine (Cytosar-U)FDA LinkGeneric 04/2024 - 01/2020
5	Dexamethasone (Maxidex)FDA LinkGeneric 04/2024 - 01/2020
5	Vinblastine (Vinblastine Sulfate)FDA Link 10/2023 - 01/2018
5	Etoposide (VP 16)FDA LinkGeneric 01/2021 - 04/2011
4	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2023 - 01/2019
4	Lenalidomide (CC 5013)FDA Link 01/2022 - 01/2017
4	NivolumabIBA 01/2022 - 01/2017
4	Monoclonal AntibodiesIBA 01/2021 - 01/2007
3	Chimeric Antigen ReceptorsIBA 01/2024 - 11/2021
3	Dacarbazine (DIC)FDA LinkGeneric 10/2023 - 01/2019
3	Bleomycin (Blenoxane)FDA LinkGeneric 01/2022 - 01/2018
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 11/2012
3	copanlisibIBA 01/2021 - 12/2017
3	Prednisone (Sone)FDA LinkGeneric 01/2021 - 01/2018
2	Bortezomib (Velcade)FDA Link 04/2024 - 11/2023
2	Brentuximab VedotinIBA 10/2023 - 04/2016
2	pembrolizumabIBA 01/2023 - 01/2020
2	PlatinumIBA 03/2022 - 01/2021
2	ibrutinibIBA 03/2022 - 01/2021
2	axicabtagene ciloleucelIBA 11/2021 - 01/2021
2	tocilizumab (atlizumab)FDA Link 11/2021 - 01/2021
2	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2021 - 01/2021
2	Vincristine (Oncovin)FDA LinkGeneric 01/2021 - 01/2019
2	Carboplatin (JM8)FDA LinkGeneric 11/2020 - 01/2020
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2020 - 01/2020
2	Carmustine (FIVB)FDA Link 01/2020 - 06/2018
2	Melphalan (Alkeran)FDA LinkGeneric 01/2020 - 04/2011
2	TOR Serine-Threonine KinasesIBA 03/2013 - 07/2012
2	Methotrexate (Mexate)FDA LinkGeneric 11/2012 - 01/2011
1	Biomarkers (Surrogate Marker)IBA 01/2024
1	AntibodiesIBA 01/2024
1	zanubrutinibIBA 11/2023
1	isatuximabIBA 02/2023
1	Programmed Cell Death 1 ReceptorIBA 02/2023
1	cemiplimabIBA 02/2023
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2023
1	Cell-Free Nucleic AcidsIBA 01/2023
1	brexucabtagene autoleucelIBA 01/2023
1	SaltsIBA 03/2022
1	Agammaglobulinaemia Tyrosine KinaseIBA 03/2022
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 02/2022
1	idelalisibIBA 01/2021
1	Biological FactorsIBA 01/2021
1	tirabrutinibIBA 01/2021
1	Antigen Receptors (Antigen Receptor)IBA 01/2021
1	6- (1H- indazol- 6- yl)- N- (4- morpholinophenyl)imidazo(1,2- a)pyrazin- 8- amineIBA 01/2021
1	venetoclaxIBA 01/2021
1	OligonucleotidesIBA 01/2021
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 11/2020
1	Cisplatin (Platino)FDA LinkGeneric 11/2020
1	FluorineIBA 01/2020
1	Procarbazine (Matulane)FDA Link 01/2019

Therapy/Procedure

20	Therapeutics 04/2024 - 05/2008
18	Stem Cell Transplantation 12/2023 - 12/2008
14	Drug Therapy (Chemotherapy) 02/2022 - 07/2012
6	Transplantation 11/2020 - 05/2015
5	Cell Transplantation 12/2017 - 01/2017
4	Radiotherapy 11/2018 - 01/2007
4	Bone Marrow Transplantation (Transplantation, Bone Marrow) 12/2017 - 12/2017
2	Induction Chemotherapy 11/2020 - 01/2017
2	BEAM regimen 01/2020 - 04/2011
2	Homologous Transplantation 01/2017 - 01/2011
1	Ligation 01/2023
1	Intravenous Infusions 01/2021
1	Immunomodulation 01/2020
1	Immunotherapy 12/2018
1	Splenectomy 12/2018